Skip to main content

Table 5 Univariate Cox regression model of clinical parameters on disease specific survival in different EOC

From: Characteristics and outcome of the COEUR Canadian validation cohort for ovarian cancer biomarkers

Residual disease HGSC EC CCC LGSC
Hazard 95.0% CI n   Hazard 95.0% CI n   Hazard 95.0% CI n   Hazard 95.0% CI n  
Ratio Lower Upper   p value Ratio Lower Upper   p va lue Ratio Lower Upper   p value Ratio Lower Upper   p value
None     206 reference     119 reference     93 reference     16 reference
< 1 cm 1.72 1.31 2.23 230 0.000 3.80 1.63 8.84 29 0.002 2.24 1.17 4.29 26 0.015 1.10 0.45 2.72 21 0.835
Suboptimal 2.90 2.28 3.70 347 0.000 15.03 5.72 39.47 10 0.000 8.30 4.38 15.76 17 0.000 2.40 1.08 5.36 27 0.033
Stage
 I     70 reference     140 reference     124 reference     13 reference
 II 1.25 0.77 2.03 136 0.376 1.91 0.80 4.61 73 0.147 2.36 1.32 4.24 54 0.004 1.32 0.29 5.91 7 0.719
 III 3.17 2.09 4.81 820 0.000 6.48 3.04 13.82 44 0.000 8.15 4.93 13.48 58 0.000 2.73 0.98 7.63 68 0.056
 IV 4.61 2.93 7.26 120 0.000 NA NA NA 5 NA 19.35 7.57 49.43 7 0.000 7.11 1.87 27.00 6 0.004
  1. Bold values highlights the statistically significant difference with the reference category
  2. NA non applicable number of cases too low, n number of patients with follow-up, HR Hazard ratio, EOC epithelial ovarian cancer, CI confidence interval, HGSC High-Grade Serous Carcinoma, EC Endometrioid Carcinoma